Skip to main content
Erschienen in: Supportive Care in Cancer 4/2014

01.04.2014 | Original Article

The persistence of symptom burden: symptom experience and quality of life of cancer patients across one year

verfasst von: Teresa L. Deshields, Patricia Potter, Sarah Olsen, Jingxia Liu

Erschienen in: Supportive Care in Cancer | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The purpose of this longitudinal study was to track the symptom experience in a sample of cancer patients, determine the persistence of cancer symptoms and symptom burden, and examine the relationship between symptoms and QOL over time.

Methods

Five hundred forty-two patients provided longitudinal data, completing surveys over a 12-month period. Patients had breast, colorectal, gynecologic, lung, or prostate cancer with stage 1, 2, or 3 disease. Surveys included the Memorial Symptom Assessment Scale and the Functional Assessment of Cancer Therapy-General Scale and were administered every 3 months. Demographic and clinical information and comorbidities were collected from the tumor registry.

Results

The number and type of symptoms experienced by patients varied by cancer type, but about 90 % of patients reported one or more symptoms—with prostate cancer patients reporting fewer symptoms and colorectal patients, more symptoms. Prostate patients also had the lowest symptom burden at every time point. Overall, symptom burden decreased over time, as did the Physical subscale for the MSAS. Quality of life was stable over time, except for physical well-being, which improved. Quality of life was negatively correlated with symptom burden at every time point.

Conclusions

The differences in symptom experience by cancer type suggest that assessment and management of symptoms must be individually tailored or at least adjusted by cancer type. While symptom burden decreased over time, residual symptom burden was still noteworthy. As quality of life was persistently negatively correlated with symptom burden, the results suggest the need for comprehensive symptom assessment and management.
Literatur
1.
Zurück zum Zitat Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA: Cancer J for Clin 62(1):10–29 Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA: Cancer J for Clin 62(1):10–29
3.
Zurück zum Zitat Portenoy RK, Thaler HT, Kornblith AB et al (1994) Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res 3:183–189PubMedCrossRef Portenoy RK, Thaler HT, Kornblith AB et al (1994) Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res 3:183–189PubMedCrossRef
4.
Zurück zum Zitat Baggott C, Dodd M, Kennedy N et al (2009) Multiple symptoms in pediatric oncology patients: a systematic review. J Pediatr Oncol Nurs 26:325–339PubMedCrossRef Baggott C, Dodd M, Kennedy N et al (2009) Multiple symptoms in pediatric oncology patients: a systematic review. J Pediatr Oncol Nurs 26:325–339PubMedCrossRef
5.
Zurück zum Zitat Chang VT, Hwang SS, Feuerman M et al (2000) Symptom and quality of life survey of medical oncology patients at a veterans affairs medical center: a role for symptom assessment. Cancer 88:1175–1183PubMedCrossRef Chang VT, Hwang SS, Feuerman M et al (2000) Symptom and quality of life survey of medical oncology patients at a veterans affairs medical center: a role for symptom assessment. Cancer 88:1175–1183PubMedCrossRef
6.
Zurück zum Zitat Kroenke K, Zhong X, Theobald D et al (2010) Somatic symptoms in patients with cancer experiencing pain or depression. Arch Intern Med 170(18):1686–1694PubMedCentralPubMedCrossRef Kroenke K, Zhong X, Theobald D et al (2010) Somatic symptoms in patients with cancer experiencing pain or depression. Arch Intern Med 170(18):1686–1694PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Cooley ME (2000) Symptoms in adults with lung cancer: a systematic research review. J Pain Sympt Manag 19:137–153CrossRef Cooley ME (2000) Symptoms in adults with lung cancer: a systematic research review. J Pain Sympt Manag 19:137–153CrossRef
8.
Zurück zum Zitat Deshields TL, Potter P, Olsen S et al (2011) Documenting the symptom experience of cancer patients. J Support Oncol 9(6):216–223PubMedCrossRef Deshields TL, Potter P, Olsen S et al (2011) Documenting the symptom experience of cancer patients. J Support Oncol 9(6):216–223PubMedCrossRef
9.
Zurück zum Zitat Cella D, Davis K, Breitbart W et al (2001) Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 19(14):3385–3391PubMed Cella D, Davis K, Breitbart W et al (2001) Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 19(14):3385–3391PubMed
10.
Zurück zum Zitat Savard J, Ivers H, Villa J et al (2011) Natural course of insomnia comorbid with cancer: an 18-month longitudinal study. J Clin Oncol 29(26):3580–3586PubMedCrossRef Savard J, Ivers H, Villa J et al (2011) Natural course of insomnia comorbid with cancer: an 18-month longitudinal study. J Clin Oncol 29(26):3580–3586PubMedCrossRef
11.
Zurück zum Zitat Andreu Y, Galdon MJ, Dura E et al (2012) A longitudinal study of psychosocial distress in breast cancer: prevalence and risk factors. Psychol Health 27(1):72–87PubMedCrossRef Andreu Y, Galdon MJ, Dura E et al (2012) A longitudinal study of psychosocial distress in breast cancer: prevalence and risk factors. Psychol Health 27(1):72–87PubMedCrossRef
12.
13.
Zurück zum Zitat Harrington CB, Hansen JA, Moskowitz M et al (2010) It’s not over when it’s over: long-term symptoms in cancer survivors- a systematic review. Int J Psych Med 40(2):163–181CrossRef Harrington CB, Hansen JA, Moskowitz M et al (2010) It’s not over when it’s over: long-term symptoms in cancer survivors- a systematic review. Int J Psych Med 40(2):163–181CrossRef
14.
Zurück zum Zitat Cleeland CS (2006) The measurement of pain from metastatic bone disease: capturing the patient’s experience. Clin Cancer Res 12(20Pt2):6236s–6242sPubMedCrossRef Cleeland CS (2006) The measurement of pain from metastatic bone disease: capturing the patient’s experience. Clin Cancer Res 12(20Pt2):6236s–6242sPubMedCrossRef
15.
Zurück zum Zitat Donovan HS, Hartenbach EM, Method MW (2005) Patient-provider communication and perceived control for women experiencing multiple symptoms associated with ovarian cancer. Gynecol Oncol 99(2):404–411PubMedCrossRef Donovan HS, Hartenbach EM, Method MW (2005) Patient-provider communication and perceived control for women experiencing multiple symptoms associated with ovarian cancer. Gynecol Oncol 99(2):404–411PubMedCrossRef
16.
Zurück zum Zitat Kim JE, Dodd MJ, Aouizerat BE et al (2009) A review of the prevalence and impact of multiple symptoms in oncology patients. J Pain Sympt Manag 37(4):715–736CrossRef Kim JE, Dodd MJ, Aouizerat BE et al (2009) A review of the prevalence and impact of multiple symptoms in oncology patients. J Pain Sympt Manag 37(4):715–736CrossRef
17.
Zurück zum Zitat Burkett VS, Cleeland CS (2007) Symptom burden in cancer survivorship. J Cancer Surviv 1(2):167–175PubMedCrossRef Burkett VS, Cleeland CS (2007) Symptom burden in cancer survivorship. J Cancer Surviv 1(2):167–175PubMedCrossRef
18.
Zurück zum Zitat Kirkova J, Davis MP, Walsh D et al (2006) Cancer symptom assessment instruments: a systematic review. J Clin Oncol 24(9):1459–1473PubMedCrossRef Kirkova J, Davis MP, Walsh D et al (2006) Cancer symptom assessment instruments: a systematic review. J Clin Oncol 24(9):1459–1473PubMedCrossRef
19.
Zurück zum Zitat Committee on Cancer Survivorship: Improving Care and Quality of Life, Institute of Medicine and National Research Council (2005) From cancer patient to cancer survivor: lost in transition. The National Academies, Washington Committee on Cancer Survivorship: Improving Care and Quality of Life, Institute of Medicine and National Research Council (2005) From cancer patient to cancer survivor: lost in transition. The National Academies, Washington
20.
Zurück zum Zitat Portenoy RK, Thaler HT, Kornblith AB et al (1994) The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 30A:1326–1336PubMedCrossRef Portenoy RK, Thaler HT, Kornblith AB et al (1994) The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 30A:1326–1336PubMedCrossRef
21.
Zurück zum Zitat Molassiotis A, Wengstrom Y, Kearney N (2010) Symptom cluster patterns during the first year after diagnosis with cancer. J Pain Sympt Manag 39:847–858CrossRef Molassiotis A, Wengstrom Y, Kearney N (2010) Symptom cluster patterns during the first year after diagnosis with cancer. J Pain Sympt Manag 39:847–858CrossRef
22.
Zurück zum Zitat Akin S, Can G, Aydiner A et al (2010) Quality of life, symptom experience and distress of lung cancer patients undergoing chemotherapy. Eur J Oncol Nurs 14:400–409PubMedCrossRef Akin S, Can G, Aydiner A et al (2010) Quality of life, symptom experience and distress of lung cancer patients undergoing chemotherapy. Eur J Oncol Nurs 14:400–409PubMedCrossRef
23.
Zurück zum Zitat Sun CC, Bodurka DC, Weaver CB et al (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13:219–227PubMedCrossRef Sun CC, Bodurka DC, Weaver CB et al (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13:219–227PubMedCrossRef
24.
Zurück zum Zitat Cella DF, Tulsky DS, Gray G et al (1993) The Functional Assessment of Cancer Therapy Scale: development and validation of the general measure. J Clin Oncol 11:570–579PubMed Cella DF, Tulsky DS, Gray G et al (1993) The Functional Assessment of Cancer Therapy Scale: development and validation of the general measure. J Clin Oncol 11:570–579PubMed
25.
Zurück zum Zitat Piccirillo J, Creech C, Zequeira R et al (1999) Inclusion of comorbidity into oncology data registries. J Registry Manag 26(2):66–70 Piccirillo J, Creech C, Zequeira R et al (1999) Inclusion of comorbidity into oncology data registries. J Registry Manag 26(2):66–70
26.
Zurück zum Zitat Kaplan MH, Feinstein AR (1974) The importance of classifying initial comorbidity in evaluating the outcome of diabetes mellitus. J Chron Dis 27:387–404PubMedCrossRef Kaplan MH, Feinstein AR (1974) The importance of classifying initial comorbidity in evaluating the outcome of diabetes mellitus. J Chron Dis 27:387–404PubMedCrossRef
27.
Zurück zum Zitat Prigozin A, Uziely B, Musgrave CF (2010) The relationship between symptom severity and symptom interference, education, age, marital status, and type of chemotherapy treatment in Israeli women with early-stage breast cancer. Oncol Nurs Forum 37(6):E411–E418PubMedCrossRef Prigozin A, Uziely B, Musgrave CF (2010) The relationship between symptom severity and symptom interference, education, age, marital status, and type of chemotherapy treatment in Israeli women with early-stage breast cancer. Oncol Nurs Forum 37(6):E411–E418PubMedCrossRef
28.
Zurück zum Zitat Oksholm T, Miaskowski C, Kongerud JS et al (2013) Does age influence the symptom experience of lung cancer patients prior to surgery? Lung Cancer 82:156–161PubMedCrossRef Oksholm T, Miaskowski C, Kongerud JS et al (2013) Does age influence the symptom experience of lung cancer patients prior to surgery? Lung Cancer 82:156–161PubMedCrossRef
29.
Zurück zum Zitat Mao JJ, Armstrong K, Bowman MA et al (2007) Symptom burden among cancer survivors: impact of age and comorbidity. J Am Board Fam Med 20(5):434–443PubMedCrossRef Mao JJ, Armstrong K, Bowman MA et al (2007) Symptom burden among cancer survivors: impact of age and comorbidity. J Am Board Fam Med 20(5):434–443PubMedCrossRef
30.
Zurück zum Zitat Cheung WY, Le LW, Gagliese L, Zimmermann C (2011) Age and gender differences in symptom intensity and symptom clusters among patients with metastatic disease. Support Care Cancer 19:417–423PubMedCrossRef Cheung WY, Le LW, Gagliese L, Zimmermann C (2011) Age and gender differences in symptom intensity and symptom clusters among patients with metastatic disease. Support Care Cancer 19:417–423PubMedCrossRef
31.
Zurück zum Zitat Kirkova J, Rybicki L, Walsh D, Aktas A (2012) Symptom prevalence in advanced cancer: age, gender, and performance status interactions. Am J Hosp Palliat Med 29(2):139–145CrossRef Kirkova J, Rybicki L, Walsh D, Aktas A (2012) Symptom prevalence in advanced cancer: age, gender, and performance status interactions. Am J Hosp Palliat Med 29(2):139–145CrossRef
32.
Zurück zum Zitat Mock V, Dow KH, Meares CJ et al (1997) Effects of exercise on fatigue, physical functioning, and emotional distress during radiation therapy for breast cancer. Oncol Nurs Forum 24(6):991–1000PubMed Mock V, Dow KH, Meares CJ et al (1997) Effects of exercise on fatigue, physical functioning, and emotional distress during radiation therapy for breast cancer. Oncol Nurs Forum 24(6):991–1000PubMed
34.
Zurück zum Zitat Savard J, Villa J, Simard S et al (2011) Feasibility of a self-help treatment for insomnia comorbid with cancer. Psychooncology 20(9):1013–1019PubMed Savard J, Villa J, Simard S et al (2011) Feasibility of a self-help treatment for insomnia comorbid with cancer. Psychooncology 20(9):1013–1019PubMed
35.
Zurück zum Zitat Council NR (2008) Cancer care for the whole patient: meeting psychosocial health needs. The National Academies, Washington Council NR (2008) Cancer care for the whole patient: meeting psychosocial health needs. The National Academies, Washington
Metadaten
Titel
The persistence of symptom burden: symptom experience and quality of life of cancer patients across one year
verfasst von
Teresa L. Deshields
Patricia Potter
Sarah Olsen
Jingxia Liu
Publikationsdatum
01.04.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 4/2014
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-2049-3

Weitere Artikel der Ausgabe 4/2014

Supportive Care in Cancer 4/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.